Albumin Quality in Oxidative and Ischemic Stress: Implications for Drug Binding and Clinical Pharmacokinetics
Abstract
Human serum albumin (HSA), the most abundant plasma protein, plays a critical role in transporting endogenous and exogenous ligands and drugs. Oxidative stress and ischemia induce structural modifications in HSA, including S-cysteinylation, sulfenylation, sulfinylation, and sulfonylation. These changes affect the Sudlow's sites and fatty acid-binding pockets, leading to altered drug affinity and pharmacokinetics. In patients with systemic inflammation or metabolic dysfunction, including sepsis, diabetes, liver disease, and cardiovascular disease, a substantial proportion-often exceeding 50%-of circulating albumin may be structurally modified. Ischemic injury produces ischemia-modified albumin via N-terminal damage, offering a rapid and reversible biomarker for hypoxia. Experimental and clinical evidence suggests that oxidative modification of HSA can either diminish or enhance drug binding, as observed with aripiprazole and methotrexate, respectively, resulting in significant interindividual variability in pharmacodynamic responses. Reduced drug-binding capacity in patients with cirrhosis and sepsis underscores the importance of evaluating albumin quality, in addition to its quantity, when optimizing drug dosing. Future work should clarify how modified HSA affects clearance pathways and whether exogenous albumin is similarly oxidized in vivo. Understanding these qualitative alterations may improve pharmacotherapy in critically ill and chronically inflamed patients.
Related
- Alu hypomethylation in ischemic stroke: Associations with selected clinical characteristics
- Clinical, single-cell, and spatial transcriptomic integration identifies an RCD-high inflammatory myeloid program for early neurological deterioration and outcome stratification after acute ischemic stroke
- Psoriasis and Bullous Pemphigoid: An Updated Review of Clinical Association, Targeted Therapy Exposures and Therapeutic Implications
- Microbiological mechanisms of immune response modulation: clinical implications
- Ginsenosides in hepatocellular carcinoma: preclinical evidence, mechanisms, and clinical implications
BibTeX
@article{ichimizu2026albumin,
title = {{Albumin Quality in Oxidative and Ischemic Stress: Implications for Drug Binding and Clinical Pharmacokinetics}},
author = {Shota Ichimizu and Kosuke Doki and Masato Homma},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
month = oct,
doi = {10.1248/bpb.b26-00232},
url = {https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00232/_article},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Albumin Quality in Oxidative and Ischemic Stress: Implications for Drug Binding and Clinical Pharmacokinetics
AU - Shota Ichimizu
AU - Kosuke Doki
AU - Masato Homma
PY - 2026
DA - 2026/10/01
JO - Biological and Pharmaceutical Bulletin
DO - 10.1248/bpb.b26-00232
UR - https://www.jstage.jst.go.jp/article/bpb/49/10/49_b26-00232/_article
AB - Human serum albumin (HSA), the most abundant plasma protein, plays a critical role in transporting endogenous and exogenous ligands and drugs. Oxidative stress and ischemia induce structural modifications in HSA, including S-cysteinylation, sulfenylation, sulfinylation, and sulfonylation. These changes affect the Sudlow's sites and fatty acid-binding pockets, leading to altered drug affinity and pharmacokinetics. In patients with systemic inflammation or metabolic dysfunction, including sepsis, diabetes, liver disease, and cardiovascular disease, a substantial proportion-often exceeding 50%-of circulating albumin may be structurally modified. Ischemic injury produces ischemia-modified albumin via N-terminal damage, offering a rapid and reversible biomarker for hypoxia. Experimental and clinical evidence suggests that oxidative modification of HSA can either diminish or enhance drug binding, as observed with aripiprazole and methotrexate, respectively, resulting in significant interindividual variability in pharmacodynamic responses. Reduced drug-binding capacity in patients with cirrhosis and sepsis underscores the importance of evaluating albumin quality, in addition to its quantity, when optimizing drug dosing. Future work should clarify how modified HSA affects clearance pathways and whether exogenous albumin is similarly oxidized in vivo. Understanding these qualitative alterations may improve pharmacotherapy in critically ill and chronically inflamed patients.
SN - 1347-5215
SN - 0918-6158
ER -